Deletion or downregulation of MHC antigens limits immunotherapy’s effectiveness, as immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors) depend on T cell recognition of tumor antigens. Here, PDCD1 is linked to neoplasm.